Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical leader developing novel therapies for cancer and immune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative information on Syndax's oncology pipeline, including revumenib for acute leukemias and axatilimab for chronic GVHD. Our curated news collection features earnings reports, partnership announcements, trial results, and FDA communications – all essential for tracking the company's progress in targeted cancer therapeutics.
Key updates include developments in menin-KMT2A pathway research, CSF-1R antibody applications, and commercial readiness efforts. Bookmark this page for streamlined access to verified SNDX news, eliminating the need to monitor multiple sources.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, announced an inducement stock option grant for its new President, Dr. Neil Gallagher. Effective April 10, 2023, Dr. Gallagher received an award to purchase 250,000 shares at an exercise price of $19.35, the closing stock price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on Dr. Gallagher's continued employment. This grant was approved by Syndax's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4). Syndax's innovative pipeline includes drugs like revumenib and axatilimab, which are in pivotal trials. Further details can be found on their official website.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a biopharmaceutical company focused on cancer therapies, announced on April 3, 2023, the granting of inducement awards to six new employees under its 2023 Inducement Plan. These awards total 121,100 shares of common stock, with an exercise price set at $20.91 per share, reflecting the closing stock price on that date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent upon the employees’ continued service. Syndax's notable pipeline includes revumenib and axatilimab, both currently in pivotal trials.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
